search
Back to results

Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery

Primary Purpose

Myopia, Myopic Astigmatism

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
WFG PRK
WFG LASIK
WFO PRK
WFO LASIK
Sponsored by
Fort Belvoir Community Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia

Eligibility Criteria

21 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Normal, healthy active adults with access to medical care at Walter Reed Health Care System.
  2. Male or female at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  3. Myopic spherical manifest refractive error from -1.00D up to -10.00D inclusive, with no more than 4.00D of manifest cylinder refractive error.
  4. Inclusion based on pre-op Central Corneal Thickness (CCT) will be assessed according to Residual Stromal Bed Thickness
  5. BSCVA of at least 20/20 in the study eye.
  6. Soft contact lens users must have removed their lenses at least two weeks prior to baseline and follow-up measurements.
  7. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline and follow-up measurements.
  8. Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50 diopters over the previous 12 months.
  9. Exhibits strong motivation for keeping the follow-up visits.
  10. Available for evaluation at Walter Reed during the 1 year follow-up period
  11. If selected, willing and available to undergo testing at Ft. Belvoir during the study period.
  12. All service members must have a signed command authorization to receive government sponsored refractive surgery. The signed command authorization will be included in the original application.
  13. Access to transportation to meet follow-up requirements.

Exclusion Criteria:

  1. Residual, recurrent or active ocular diseases or congenital corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
  2. History of any previous eye surgery or trauma, including previous refractive surgery.
  3. Dry eye as reflected by Schirmer's test, subjective complaints or symptoms of dry eye, findings during slit lamp exam that would be consistent with dry eye (e.g. superficial punctuate keratitis).
  4. Corneal thickness insufficient to allow the residual remaining stromal bed to be no less than 300 microns in each eye. The residual stromal bed thickness will be determined by subtracting both the LASIK flap thickness and depth of the ablation from the total central corneal thickness measured by pachymetry.
  5. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. This is standard of care exclusion for refractive surgery at the Walter Reed Refractive Surgery Center because of the medications that are routinely given as part of the procedures. Standard of care analgesia consists of medications (e.g. narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not known, however, physical dependence in the neonate may occur if the mother is given narcotics. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy.
  6. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
  7. Significant corneal neovascularization.
  8. Progressive myopia or keratoconus.
  9. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  10. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
  11. Any physical or mental impairment which would preclude participation in any of the examinations.
  12. Inability to meet the mandated follow-up visit schedule for any reason such as duty hours, impending deployments, or PCS.

Sites / Locations

  • Walter Reed National Military Medical Center
  • Fort Belvoir Community Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Wavefront guided (WFG) PRK

WFG LASIK

Wavefront optimized (WFO) PRK

WFO LASIK

Arm Description

Outcomes

Primary Outcome Measures

visual outcomes
Visual outcomes will be measured in terms of: number of eyes achieving uncorrected visual acuity (UDVA) 20/20 or better. number of eyes maintaining one Snellen line of corrected distance visual acuity (CDVA). number of eyes within 0.50 diopter of manifest spherical equivalent.
objective image quality
as measured by wavefront aberrometry
military task performance
as measured by threshold target identification and night firing range
visual performance
as measured by contrast sensitivity

Secondary Outcome Measures

Full Information

First Posted
March 31, 2010
Last Updated
March 12, 2015
Sponsor
Fort Belvoir Community Hospital
Collaborators
Walter Reed National Military Medical Center, US Army Night Vision and Electronic Sensors Directorate
search

1. Study Identification

Unique Protocol Identification Number
NCT01097525
Brief Title
Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery
Official Title
Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fort Belvoir Community Hospital
Collaborators
Walter Reed National Military Medical Center, US Army Night Vision and Electronic Sensors Directorate

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine the effect of two types of wavefront modalities (WFG vs. WFO) and two types of refractive surgery (PRK vs. LASIK) on visual and military task performance after laser refractive surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia, Myopic Astigmatism

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
224 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Wavefront guided (WFG) PRK
Arm Type
Active Comparator
Arm Title
WFG LASIK
Arm Type
Active Comparator
Arm Title
Wavefront optimized (WFO) PRK
Arm Type
Active Comparator
Arm Title
WFO LASIK
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
WFG PRK
Intervention Type
Procedure
Intervention Name(s)
WFG LASIK
Intervention Type
Procedure
Intervention Name(s)
WFO PRK
Intervention Type
Procedure
Intervention Name(s)
WFO LASIK
Primary Outcome Measure Information:
Title
visual outcomes
Description
Visual outcomes will be measured in terms of: number of eyes achieving uncorrected visual acuity (UDVA) 20/20 or better. number of eyes maintaining one Snellen line of corrected distance visual acuity (CDVA). number of eyes within 0.50 diopter of manifest spherical equivalent.
Time Frame
12 months postoperatively
Title
objective image quality
Description
as measured by wavefront aberrometry
Time Frame
12 months postoperatively
Title
military task performance
Description
as measured by threshold target identification and night firing range
Time Frame
6 months postoperatively
Title
visual performance
Description
as measured by contrast sensitivity
Time Frame
12 months postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Normal, healthy active adults with access to medical care at Walter Reed Health Care System. Male or female at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability. Myopic spherical manifest refractive error from -1.00D up to -10.00D inclusive, with no more than 4.00D of manifest cylinder refractive error. Inclusion based on pre-op Central Corneal Thickness (CCT) will be assessed according to Residual Stromal Bed Thickness BSCVA of at least 20/20 in the study eye. Soft contact lens users must have removed their lenses at least two weeks prior to baseline and follow-up measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline and follow-up measurements. Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50 diopters over the previous 12 months. Exhibits strong motivation for keeping the follow-up visits. Available for evaluation at Walter Reed during the 1 year follow-up period If selected, willing and available to undergo testing at Ft. Belvoir during the study period. All service members must have a signed command authorization to receive government sponsored refractive surgery. The signed command authorization will be included in the original application. Access to transportation to meet follow-up requirements. Exclusion Criteria: Residual, recurrent or active ocular diseases or congenital corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts. History of any previous eye surgery or trauma, including previous refractive surgery. Dry eye as reflected by Schirmer's test, subjective complaints or symptoms of dry eye, findings during slit lamp exam that would be consistent with dry eye (e.g. superficial punctuate keratitis). Corneal thickness insufficient to allow the residual remaining stromal bed to be no less than 300 microns in each eye. The residual stromal bed thickness will be determined by subtracting both the LASIK flap thickness and depth of the ablation from the total central corneal thickness measured by pachymetry. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. This is standard of care exclusion for refractive surgery at the Walter Reed Refractive Surgery Center because of the medications that are routinely given as part of the procedures. Standard of care analgesia consists of medications (e.g. narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not known, however, physical dependence in the neonate may occur if the mother is given narcotics. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex). Significant corneal neovascularization. Progressive myopia or keratoconus. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course. Any physical or mental impairment which would preclude participation in any of the examinations. Inability to meet the mandated follow-up visit schedule for any reason such as duty hours, impending deployments, or PCS.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kraig S Bower, MD
Organizational Affiliation
The Wilmer Eye Institute, Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walter Reed National Military Medical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20889
Country
United States
Facility Name
Fort Belvoir Community Hospital
City
Fort Belvoir
State/Province
Virginia
ZIP/Postal Code
22060
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery

We'll reach out to this number within 24 hrs